HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Polypodium leucotomos supplementation in the treatment of scalp actinic keratosis: could it improve the efficacy of photodynamic therapy?

AbstractBACKGROUND:
Actinic keratoses (AKs) are a common premalignant skin condition. Many treatments are available for AKs. Photodynamic therapy (PDT) is one of the most effective treatments. However, major concerns exist on the possibility of PDT-induced DNA-mutagenesis/immunosuppression, leading to AKs recurrence/treatment failure. An extract (PLE) from the fern polypodium leucotomos reduces UV-induced immunosuppression and mutagenesis.
OBJECTIVE:
To assess the ability of PLE to enhance the efficacy of PDT treatment, reducing AKs recurrence on the scalp.
MATERIALS AND METHODS:
Thirty-four bald patients presenting at least two AKs on the scalp were alternatively assigned to two groups. Both groups underwent two PDT-sessions one-week apart. The first group began oral PLE supplementation one week after the last PDT session. Evaluation of the effect of PLE supplementation was performed by direct inspection of the bald areas, lesions count, and photodynamic diagnosis assessment at 2 and 6 months.
RESULTS:
Both groups were homogeneous in terms of skin phototype and previous UV exposure. Mean age was 75.7 ± 7.8 years and 76.5 ± 5.5 years, respectively. Both treatment modalities were successful in reducing AKs number (p < .001). However, PLE supplementation increased clearance rate compared with PDT alone (p = .040).
CONCLUSION:
Polypodium leucotomos improves PDT clearance and decreases AK recurrence rate at 6 months, suggesting its use as a complementary agent in the treatment of field cancerization.
AuthorsMatteo Auriemma, Marta Di Nicola, Salvador Gonzalez, Stefano Piaserico, Alessandra Capo, Paolo Amerio
JournalDermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] (Dermatol Surg) Vol. 41 Issue 8 Pg. 898-902 (Aug 2015) ISSN: 1524-4725 [Electronic] United States
PMID26218723 (Publication Type: Journal Article, Randomized Controlled Trial)
Chemical References
  • Photosensitizing Agents
  • Plant Extracts
  • methyl 5-aminolevulinate
  • Aminolevulinic Acid
Topics
  • Aged
  • Aged, 80 and over
  • Aminolevulinic Acid (analogs & derivatives, therapeutic use)
  • Humans
  • Keratosis, Actinic (drug therapy)
  • Male
  • Photochemotherapy
  • Photosensitizing Agents (therapeutic use)
  • Phytotherapy
  • Plant Extracts (therapeutic use)
  • Polypodium (chemistry)
  • Recurrence
  • Scalp Dermatoses (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: